Drug Farm Raises $55 Million Series D to Advance Dual-Indication ALPK1 Programs 28 minutes ago AnaIn Clinical TrialsFunding RoundsVenture Capital
Inside the Fight Over Sean Kaufman: What a Vaccine Skeptic’s Nomination Reveals About HHS’s Next Chapter 33 minutes ago AnaIn Breaking NewsLeadersPharma Industry UpdatesTop Stories
ProMIS Neurosciences Reports First Human Evidence of Dose-Dependent Amyloid-Oligomer Reduction at AAIC 2026 36 minutes ago AnaIn BreakthroughsClinical TrialsResearch Updates
Biotech M&A Roars Back: Why 2026 Is Already the Best Dealmaking Year in Seven Years 38 minutes ago AnaIn Featured AnalysisPartnershipsTop StoriesVenture Capital
Bausch + Lomb Discontinues Glaucoma Eye Drop Program After Phase 2 Trial Misses Primary Endpoint 1 day ago AnaIn Clinical TrialsPharma Industry Updates
Q32 Bio Reports 36-Week Data From Expanded Alopecia Areata Trial, Advancing Bempikibart Toward Pivotal Studies 1 day ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisTop Stories
Vaccinex Reports New Glial Biomarker Data for Pepinemab, Outlines Path to Expanded Phase 2b Alzheimer’s Study 1 day ago AnaIn Deals
Beyond Amyloid: AAIC 2026 Signals a Broader, More Testable Alzheimer’s Pipeline 1 day ago AnaIn Clinical TrialsFeatured AnalysisIndustry ConferencesResearch Updates
Celea Therapeutics Launches With $180 Million to Challenge Pirfenidone in IPF 6 days ago AnaIn DealsFunding RoundsResearch UpdatesStartups
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy for Australian Market 6 days ago AnaIn BreakthroughsResearch Updates
Epcoritamab Clears Phase 3 Bar in Relapsed Large B-Cell Lymphoma 6 days ago AnaIn Clinical TrialsPartnershipsResearch Updates
Vertex’s Casgevy Clears FDA Hurdle for Youngest Sickle Cell Patients 6 days ago AnaIn Breaking NewsBreakthroughsFDA ApprovalsPartnerships
No Single Mechanism Solves Epilepsy: What Bright Minds’ BMB-101 Data Tells Us About the Future of Seizure Control 7 days ago AnaIn AI & DataFeatured AnalysisLeadersPeopleResearch Updates
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy Altuviiio, Widening Treatment Options for Australian Patients 1 week ago AnaIn BreakthroughsClinical TrialsPharma Industry UpdatesTop Stories
Slate Medicines Emerges With $130 Million to Chase PACAP, a Migraine Target Distinct From CGRP 2 weeks ago AnaIn DealsFunding RoundsInnovationInvestments
